What Is LIT-001? Definition and What Research Reports

Definition

LIT-001 is the laboratory code name for a small-molecule agonist of the oxytocin receptor (OXTR). It was introduced in the medicinal chemistry literature as the first nonpeptide oxytocin receptor agonist shown to improve social interaction after peripheral administration in a mouse model of autism, as reported by the researchers who described the compound (PMID 30199637). In plain terms, LIT-001 is a synthetic chemical designed to switch on the same receptor that the hormone oxytocin binds to, but without being a peptide itself. It exists as a research tool and as a starting point for drug-discovery programmes; it is not an approved medicine, and the published work available on it is preclinical.

What Class of Molecule Is It?

LIT-001 belongs to the class of nonpeptide receptor agonists: organic small molecules that bind a receptor normally activated by a peptide or protein hormone. Oxytocin itself is a nine-amino-acid cyclic neuropeptide. Small molecules such as LIT-001 are chemically unrelated to that structure, which is the point of the design approach — peptides are typically degraded quickly by peptidases, are poorly absorbed after oral dosing, and cross the blood–brain barrier only to a limited degree. Reviews of oxytocin receptor pharmacology have described nonpeptide agonists as one of the main strategies pursued to obtain more drug-like ways of engaging the oxytocin system (PMID 36744978).

Why it appears in peptide glossaries

LIT-001 is frequently indexed alongside peptides because its target, the oxytocin receptor, is a peptide-hormone receptor, and because it is discussed in the same research literature as oxytocin analogues such as carbetocin. Strictly speaking, LIT-001 is not a peptide — it is a synthetic small molecule. Readers scanning peptide reference material will usually encounter it under headings about oxytocin receptor agonism rather than under peptide chemistry.

Where the Term Comes From

The name follows the common convention for preclinical compounds: a short alphabetic prefix from the originating laboratory or series, plus a number identifying the analogue. LIT-001 entered the literature in 2018 in a Journal of Medicinal Chemistry report describing its synthesis, receptor selectivity work, and behavioural testing in mice (PMID 30199637). Subsequent papers from several groups have used the same designation, so the term is stable in the indexed literature and refers to a single defined chemical entity rather than a family of related products.

How the Term Is Used in Research

In published studies, LIT-001 is generally used as a pharmacological probe: a way of asking what happens when the oxytocin receptor is activated systemically, without the pharmacokinetic limitations of injecting oxytocin itself. Typical usage patterns in the literature include:

• As a comparator or tool compound in behavioural neuroscience experiments on social behaviour and cognition.
• As a test agent in rodent models of neurodevelopmental conditions, where oxytocin signalling is hypothesised to be altered.
• As a probe for oxytocin receptor involvement in pain circuits and in reward-related behaviours such as alcohol drinking.
• As a chemical starting point discussed in medicinal chemistry reviews of oxytocin receptor drug discovery (PMID 36744978).

What the Published Literature Reports

The evidence base is preclinical. The original characterisation reported that LIT-001 activated the oxytocin receptor and that peripheral administration improved social interaction deficits in a mouse model of autism (PMID 30199637). A later study in a neurodevelopmental rat model of schizophrenia reported pro-social and pro-cognitive effects of the same compound (PMID 37866191). In a separate line of work, researchers described a nonpeptide oxytocin receptor agonist producing durable relief of inflammatory pain in a rodent model (PMID 32080303), and a 2023 study investigated a paraventricular thalamic–nucleus accumbens circuit implicated in pain sensation and non-opioid analgesia involving oxytocin receptor signalling (PMID 37084858).

Study map

Reviews that place it in context

Narrative reviews of oxytocin receptor pharmacology have discussed molecular and therapeutic approaches to targeting OXTR, including the rationale for nonpeptide agonists (PMID 36744978). A separate review examined current perspectives on oxytocin in relation to Alzheimer's disease-related symptoms (PMID 41503900). Reviews of this kind describe hypotheses and research directions rather than demonstrating clinical outcomes.

Safety and Adverse Events: What Studies Report

The publications summarised on this page were animal and chemistry studies focused on receptor pharmacology and behavioural outcomes; none of them reported human clinical trial safety data for LIT-001 (PMID 30199637, PMID 37866191, PMID 32080303). Because oxytocin receptors are expressed in the uterus, breast, heart and vasculature as well as in the brain, reviews of oxytocin receptor pharmacology have noted that selectivity and peripheral receptor engagement are central questions for any agonist in this class (PMID 36744978). Absence of reported adverse events in small preclinical experiments is not the same as an established safety profile. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

Regulatory and Practical Status

LIT-001 has not been approved as a medicine by the U.S. Food and Drug Administration, the European Medicines Agency or comparable regulators, and it does not appear in the verified literature as the subject of a completed human trial. Compounds at this stage of development are typically handled as research-use-only (RUO) chemicals in laboratory settings, where their handling is governed by institutional and jurisdictional research rules rather than by pharmacy practice standards.

Common Points of Confusion

• LIT-001 vs. oxytocin: oxytocin is the endogenous nine-amino-acid neuropeptide; LIT-001 is a synthetic nonpeptide that activates the same receptor (PMID 30199637).
• LIT-001 vs. carbetocin: carbetocin is a peptide oxytocin analogue; LIT-001 is not a peptide analogue at all.
• Preclinical vs. clinical: all behavioural findings cited here came from mice, rats, prairie voles or zebrafish, not from people.
• Preprint vs. journal version: the prairie vole pair-bonding work exists both as a preprint (PMID 38798348) and as a peer-reviewed article (PMID 39009600), which can make the same data look like two separate studies.

References

• LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism (Journal of Medicinal Chemistry, 2018)
• A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain (Scientific Reports, 2020)
• Oxytocin and its receptor: molecular and therapeutic approaches (Biologie Aujourd'hui, 2022)
• Male-selective effects of oxytocin agonism on alcohol intake: behavioral assessment in socially housed prairie voles and involvement of RAGE (Neuropsychopharmacology, 2023)
• Neural and molecular investigation into the paraventricular thalamic-nucleus accumbens circuit for pain sensation and non-opioid analgesia (Pharmacological Research, 2023)
• Pro-social and pro-cognitive effects of LIT-001, a novel oxytocin receptor agonist in a neurodevelopmental model of schizophrenia (European Neuropsychopharmacology, 2024)
• Effects of oxytocin receptor agonism on acquisition and expression of pair bonding in male prairie voles (Translational Psychiatry, 2024)
• Effects of Oxytocin Receptor Agonism on Acquisition and Expression of Pair Bonding in Male Prairie Voles (Research Square, 2024)
• Unraveling the socio-cognitive consequences of KCC2 disruption in zebrafish: implications for neurodevelopmental disorders and therapeutic interventions (Frontiers in Molecular Neuroscience, 2024)
• Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms (Current Alzheimer Research, 2026)